Stelios Papadopoulos - BG Medicine Insider

BGMD -- USA Stock  

USD 0.021  0.009  30.00%

Dr. Stelios B. Papadopoulos, Ph.D., is an Independent Director of BG Medicine, Inc. He has served as Chairman of Fondation Sant, a private charitable foundation whose mission is to provide support for research and education in the life sciences. Dr. Papadopoulos served as Vice Chairman of Cowen and Company, LLC from 2003 until 2006 and as Managing Director from 2000 until 2003. While at Cowen and Company, LLC, he worked as an investment banker focused on the biotech and pharmaceutical sectors. Prior to joining Cowen and Company, LLC, he worked as an investment banker at PaineWebber, Incorporated, from 1987 to 2000, where he was Chairman of PaineWebber Development Corporationration, a PaineWebber subsidiary focusing on biotechnology from 1996 to 2000. Dr. Papadopoulos is a cofounder and Chairman of the Board of Exelixis, Inc. Dr. Papadopoulos currently serves as chairman of the board of Regulus Therapeutics, Inc. and Biogen Inc. and he is a member of the board of directors of Joule Unlimited, Inc. During the past five years, he also served on the board of directors of Anadys Pharmaceuticals, Inc., and Cellzome, Inc. . He is also a member of the board of visitors of Duke University School of Medicine and the board of Global Advisors of the Duke Institute of Health Innovation
Age: 68  Director Since 2012  MBA    
Papadopoulos holds a Ph.D. in biophysics and an M.B.A. in finance, both from New York University.

Stelios Papadopoulos Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (75.95) % which means that it has lost $75.95 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (902.64) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Showing few of many executives


Roy WhitfieldIllumina
JeanPaul MangeolleCharles River Laboratories Inte
Matthew NortonMedpace Holdings
George MassaroCharles River Laboratories Inte
Cornelius McCarthyMedpace Holdings
Colin HillBioTelemetry
Stephen ChubbCharles River Laboratories Inte
Edward DriscollNatera
George ScangosAgilent Technologies
Brian CarleyMedpace Holdings
Joseph FrickBioTelemetry
John ThompsonIllumina
Michael WyzgaExact Sciences Corporation
Daniel BradburyIllumina
Savita AcharyaNational Research Corporation
Gail MarcusNatera
Richard ReeseCharles River Laboratories Inte
James HealyNatera
Sally CrawfordExact Sciences Corporation
Robert KraftMedpace Holdings
Katherine NapierExact Sciences Corporation

Entity Summary

BG Medicine, Inc. engages in development and commercialization of diagnostic products used to guide the patients suffering from heart failure and related disorders in the United States. BG Medicine, Inc. was founded in 2000 and is headquartered in Waltham, Massachusetts. BG Medicine operates under Diagnostics Research classification in USA and traded on OTC Market. It employs 5 people.BG Medicine (BGMD) is traded on OTC Market in USA. It is located in 303 Wyman Street and employs 5 people.

BG Medicine Leadership Team

James Connor, Director
Harry Wilcox, Director
Stelios Papadopoulos, Independent Director
Aram Adourian, Chief Scientific Officer and Sr. VP
Stephen Hall, CFO, Principal Accounting Officer, Executive VP and Treasurer
Jeffrey Luber, Director
Paul Sohmer, President CEO, Director
Noubar Afeyan, Founder
James OConnor, Independent Director

Stock Performance Indicators

Current Sentiment - BGMD

BG Medicine Investor Sentiment

Most of Macroaxis users are currently bullish on BG Medicine. What is your opinion about investing in BG Medicine? Are you bullish or bearish?
98% Bullish
2% Bearish

BG Medicine Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for BG Medicine and Illumina. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Companies Directory module to evaluate performance of over 100,000 stocks, funds, and etfs against different fundamentals.